Upgrade to SI Premium - Free Trial

Arcturus Therapeutics (ARCT)

10.68 -0.39 (3.52%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/11/26)

Latest Headlines

Form SCHEDULE 13G/A Arcturus Therapeutics Filed by: FEDERATED HERMES, INC. October 7, 2026 7:17 AM - SEC Filing Arcturus Therapeutics (ARCT) Reiterated at Overweight by Cantor Fitzgerald September 24, 2026 7:17 AM - StreetInsider Arcturus Therapeutics (ARCT) PT Lowered to $20 at BTIG September 24, 2026 5:40 AM - StreetInsider Citi Upgrades Arcturus Therapeutics (ARCT) to Buy September 24, 2026 2:44 AM - StreetInsider Form 8-K Arcturus Therapeutics For: Sep 23 September 23, 2026 4:12 PM - SEC Filing Arcturus shares Phase 2 OTC data, unveils new mRNA platform September 23, 2026 4:01 PM - StreetInsider Arcturus Therapeutics Announces Interim OTC Deficiency Phase 2 Results and Introduces LUNAR 2.0™ Next-Generation mRNA Delivery Platform September 23, 2026 4:01 PM - BizWire Arcturus Therapeutics to present Phase 2 OTC deficiency data September 18, 2026 9:00 AM - StreetInsider Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform September 18, 2026 9:00 AM - BizWire Form 8-K Arcturus Therapeutics For: Aug 25 August 25, 2026 6:05 AM - SEC Filing Arcturus Therapeutics (ARCT) Tops Q2 EPS by 21c August 6, 2026 5:14 PM - StreetInsider Form 10-Q Arcturus Therapeutics For: Jun 30 August 6, 2026 4:28 PM - SEC Filing Form 8-K Arcturus Therapeutics For: Aug 06 August 6, 2026 4:07 PM - SEC Filing Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress August 6, 2026 4:01 PM - BizWire Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on Aug 6, 2026 July 28, 2026 4:01 PM - BizWire Full Article List